Lundbeck’s Vyepti Sales Disappoint But Lower Costs Boost Profitability
Danish Firm Hoping For More From Migraine Drug
Sales for the migraine product were lower in Q4 than consensus forecasts projected, but reduced costs have pushed yearly earnings beyond expectations.
